Drugs / 611
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06324812 | Jul 2024 → May 2026 | atopic eczema | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 611 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06324812 ↗ |
| Modality | Monoclonal antibody | “Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611)” NCT06324812 ↗ |
| Route | Subcutaneous | “subcutaneous injection，611 450/600mg (loading dose) + 300mg once every 2 weeks/4 weeks” NCT06324812 ↗ |